2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Pathology, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Biological Therapies, Monoclonal Antibody Therapy, Non-Biological Therapies, Anticoagulant Drugs, Pharmacology, Women’s Health, Adverse Events, Artificial Intelligence (AI), Generative AI, Machine Learning, Natural Language Processing, Biological Processes, Apoptosis, Genomics, Hematopoiesis, Molecular Biology, Clinical Practice (Health Services and Quality), Diseases, Bleeding and Clotting, Bleeding Disorders, Platelet Disorders, Thromboembolism, Thrombotic Disorders, VWD, Genetic Disorders, Immunology, Autoimmune Disorders, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, Translational Research, MDS, MPN, CMML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

5529 A Canadian multicenter comparison of treatment trends and outcomes for essential thrombocytosis patients with extreme thrombocytosis

Christine Wu, MD, Shireen Sirhan, MD,FRCP2, Natasha Szuber, MD, MSc3, Michaël Harnois, MSc, MBA4, Lynda Foltz, MD5, Caitlin Killick6, Dawn Maze Sr, MD7, Shuang Lu8, Sonia Cerquozzi, MD, FRCPC9
1 University of Calgary, Calgary, Alberta, Canada
2 McGill University, Montreal, Canada
3 University of Montreal, Montreal, Quebec, Canada
4 Groupe québécois de recherche en LMC-NMP, Montreal, Quebec, Canada
5 University of British Columbia, Vancouver, British Columbia, Canada
6 University of British Columbia, Vancouver, British Columbia, Canada
7 University of Toronto, Toronto, Ontario, Canada
8 University of Calgary, Calgary, Alberta, Canada
9 University of Calgary, Calgary, Alberta, Canada

Introduction:
Essential thrombocythemia (ET) is a myeloproliferative neoplasm defined by clonal thrombocytosis. There is a subset of ET patients with extreme thrombocytosis (EXT), defined as having a platelet count >1000 x 10^9/L. EXT has not consistently been associated with thrombotic events, and has been linked with an increased risk of acquired von Willebrand syndrome (aVWS) and hemorrhagic complications. Whether all patients with EXT require cytoreduction and its impact in mitigating thrombosis and/or hemorrhage risk remains unknown.

Objectives:
We evaluated baseline characteristics, treatment patterns, and clinical outcomes among ET patients with and without EXT across four Canadian centers. Clinical outcomes included arterial and venous thrombosis, and bleeding events among ET patients stratified by platelet count (> or < 1000 x 10^9/L), to provide real-world data on this population and further understand their management across Canada.  

Methods:
This was a multicenter retrospective study from four Canadian cities (Calgary, Montreal (Groupe québécois de recherche en LMC-NMP), Vancouver, and Toronto) of patients >18 years old who met diagnostic criteria for ET between 2008-2022 based on the revised 2016 WHO criteria. Descriptive statistics were used to summarize baseline characteristics and bleeding and thrombosis. A multivariable logistic regression model was used to evaluate association between platelet count (<1000 vs. >1000) and bleeding and thrombosis, adjusting for demographic characteristics. A univariable logistic regression model was used to evaluate association between ASA/anticoagulation/VWF activity and bleeding. 

Results:
Our study included 397 patients, of which 116 (29.22%) were EXT at diagnosis. Median age was 45 years (range: 8-85) in EXT compared to 62 years (range: 23-96) in standard ET group. There was a female preponderance in both cohorts (62.93% in EXT compared to 66.55% non-EXT). Within the EXT cohort, CALR mutation was predominant (35.34%), followed by JAK2+ (27.59%), triple-negative (11.31%), and MPL (1.72%). Within the non-EXT cohort, JAK2+ mutation was most frequent (70.46%), followed by CALR (11.74%), triple-negative (3.91%), and MPL (3.56%). Testing for aVWS was available for 32.78% of the EXT cohort and 6.05% of the non-EXT cohort. Of those tested, aVWS (vWF activity <30%) was found in 15.79% of EXT compared to 17.65% of non-EXT. Despite the risk of aVWS in EXT, ASA was used in 67.24% of patients compared to 53.02% in non-EXT. Anticoagulation was initiated in 5.17% of EXT and 6.76% of the other cohort. Cytoreduction was started in 72.41% of EXT and 78.65% in non-EXT. 

Bleeding events occurred in 10.34% of EXT and in 9.61% of non-EXT (P=0.8227), with median time-to-event of 1.76 years and 4.46 years, respectively. aVWS was associated with a higher log-odds of bleeding (4.875, p=0.0297). ASA use was not a significant predictor for bleeding events (P=0.3312). Arterial thrombosis occurred in 1.98% of EXT and in 4.24% of non-EXT patients (P=0.3335), with median time-to-event of 5.01 years and 4.21 years, respectively. Venous thrombosis occurred in 3.45% of EXT and 3.56% of non-EXT patients (P=0.9570), with median time-to-event of 3.24 years and 4.55 years, respectively. Male sex (P=0.0639, P=0.6056), age >60 years (P=0.7921, P=0.426), and leukocyte count >10 × 10?/L (P=0.9327, P=0.9794) were not identified as significant predictors for arterial or venous thrombosis. Anticoagulation use was found to be a predictor for both arterial (P=0.0030) and venous thrombosis (P<0.0001).

Conclusions:
Our study confirms previously outlined differences in the characteristics of patients with EXT with regards to age, gender, and driver mutation. Although EXT patients demonstrated a distinct clinical phenotype, thrombotic and bleeding outcomes were comparable to those of patients without EXT. The low incidence of outcomes underscores the need for studies with longer follow-up periods to characterize the long-term trajectory of these patients, as well as prognostic factors that influence thrombosis and bleeding. The retrospective design has limitations of potential selection bias, missing data, and heterogeneity in management across centers. Prospective studies are warranted to validate these observations. We have also created a subsequent Canadian hematology survey to identify current management practices and gaps in care for future development of standardized guidelines.

Christine Wu, MD: No relevant conflicts of interest to declare.